Edmond DE Rothschild Holding S.A. Buys 62,699 Shares of Zoetis Inc. $ZTS

Key Points

• Edmond DE Rothschild Holding S.A. increased its stake in Zoetis Inc. by 23.4%, owning 330,181 shares worth approximately $54.36 million.
• Zoetis reported an EPS of $1.76 for the latest quarter, surpassing analysts' estimates of $1.62 and achieving a revenue of $2.46 billion.
• The stock has a consensus rating of "Moderate Buy" from analysts, with an average price target of $202.43.

Edmond DE Rothschild Holding S.A. raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 23.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 330,181 shares of the company's stock after buying an additional 62,699 shares during the quarter. Zoetis comprises about 1.0% of Edmond DE Rothschild Holding S.A.'s portfolio, making the stock its 23rd largest position. Edmond DE Rothschild Holding S.A. owned about 0.07% of Zoetis worth $54,364,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Lindbrook Capital LLC lifted its position in shares of Zoetis by 1.8% during the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company's stock valued at $612,000 after acquiring an additional 65 shares during the period. Quotient Wealth Partners LLC lifted its position in shares of Zoetis by 2.3% during the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company's stock valued at $521,000 after acquiring an additional 72 shares during the period. Broadway Wealth Solutions Inc. lifted its position in shares of Zoetis by 4.4% during the 1st quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company's stock valued at $287,000 after acquiring an additional 73 shares during the period. Menard Financial Group LLC lifted its position in shares of Zoetis by 3.8% during the 1st quarter. Menard Financial Group LLC now owns 2,032 shares of the company's stock valued at $305,000 after acquiring an additional 75 shares during the period. Finally, Moseley Investment Management Inc. lifted its position in shares of Zoetis by 1.4% during the 1st quarter. Moseley Investment Management Inc. now owns 5,719 shares of the company's stock valued at $942,000 after acquiring an additional 77 shares during the period. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

ZTS has been the subject of a number of recent research reports. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler boosted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Leerink Partnrs lowered shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Zoetis has an average rating of "Moderate Buy" and a consensus price target of $202.43.

Zoetis Stock Down 0.9%

Shares of NYSE ZTS traded down $1.44 during trading on Monday, hitting $151.88. The stock had a trading volume of 3,312,971 shares, compared to its average volume of 3,044,883. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The company has a market capitalization of $67.31 billion, a PE ratio of 26.14, a PEG ratio of 2.46 and a beta of 0.88. The firm has a fifty day moving average of $153.16 and a two-hundred day moving average of $157.73.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the prior year, the business posted $1.56 EPS. The business's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.